GSK–Relation Therapeutics: drug target discovery, 202412– two collab $30m upfront + $263m milestones + royalties in fibrotic diseases + osteoarthritis

	Period	2024-12-10
	Region	ALL
	Partner, 1st	GSK plc (LSE: GSK, NYSE: GSK)
	Group	GSK (Group)
	Partner, 2nd	Relation Therapeutics Ltd.
	Product	drug target identification
	Product 2	Lab-in-the-Loop platform (Relation Therapeutics)
	Index term	Relation Therapeutics–GSK: investment, 202412 equity investment $15m in connection with strategic collaborations
	Person	Khavandi, Kaivan (GSK 202412 SVP Global Head of Respiratory/Immunology RnD)

Relation Therapeutics Ltd.. (12/10/24). "Press Release: Relation Announces Two Strategic Collaborations with GSK to Advance Therapeutics for Fibrotic Diseases and Osteoarthritis". London.

Relation, an industry leader in deploying computation and experimentation to drug discovery, today announced two multi-program strategic collaborations with GSK. The collaborations will focus on the identification and validation of novel therapeutic targets for fibrotic diseases and osteoarthritis. These debilitating diseases affect millions of patients worldwide and represent areas of significant unmet medical need.

“These diseases have few treatments that address their root causes,” said David Roblin, CEO of Relation. “By combining Relation’s patient-centric discovery platform with GSK’s global scale and expertise, we have the potential to accelerate the development of transformative medicines for patients who have long awaited new therapies.”

Roblin continued: “Our approach of generating data directly from patient tissue allows us to build a comprehensive picture of the underlying human disease biology at scale. This, combined with our deployment of machine learning, enables us to make unprecedented inferences about how to effectively intervene in disease processes.”

Under the terms of both agreements, Relation will receive a total upfront payment from GSK of $45 million which comprises an equity investment of $15 million. In addition, Relation will be eligible to receive success-based collaboration payments of up to $63 million, as well as potential preclinical, development, commercial, and sales milestone payments averaging $200 million per target across both deals, along with tiered royalties on net sales of products.

Relation will lead observational studies to generate two unique functional disease data sets and Relation’s Lab-in-the-Loop platform will analyse this data by integrating human genetics, single-cell multi-omics directly from human tissue, functional assays, and machine learning to discover novel disease targets. This approach minimises the risk of clinical failure by ensuring targets are robustly validated before entering the clinic. Relation will apply its platform to a number of related fibrotic conditions and also osteoarthritis. GSK will have worldwide development and commercialisation rights to any resulting targets.

“Working with Relation enables us to gain deep and precise insights into human causal biology and apply these to therapeutic discovery through a data-driven approach, supported by Relation’s proprietary platform,” said Kaivan Khavandi, SVP, Global Head of Respiratory/Immunology R&D at GSK. “The resulting targets will be supported by robust translational packages, which will in turn provide clarity on deployment in early clinical evaluation, ultimately supporting our broader portfolio ambition to develop new medicines for fibrotic diseases and osteoarthritis – where there remains significant unmet medical need.”

About Relation

Relation is a platform biotechnology company developing medicines for diseases with significant unmet need. Relation’s Lab-in-the-Loop platform combines human genetics, single-cell multi-omics directly from human tissue, functional assays, and machine learning to discover novel disease interventions. The company has programmes across metabolic and immune diseases. To date, the company has raised over $80 million from leading investors, including DCVC, Magnetic, GSK, NVIDIA NVentures, Hitachi Ventures, Khosla, ARK Ventures and Deerfield.

For media inquiries, please contact:
Rosie Rodriguez
[email protected]